hypertens
divers
ill
interlink
cerebr
cardiovascular
cv
renal
abnorm
present
maladi
treat
focus
reninangiotensin
system
ra
voltageg
calcium
channel
peripher
vasodil
renal
sympathet
nervou
system
cardiovascular
renal
abnorm
associ
overactiv
ra
constrain
angiotensinconvert
enzym
inhibitor
acei
angiotensin
ii
angii
receptor
blocker
arb
renin
inhibitor
latter
new
player
old
system
renin
catalyz
convers
angiotensinogen
angiotensin
angi
overcom
inhibit
renin
preliminari
step
eventu
hinder
occurr
cascad
event
ra
variou
peptidomimet
firstgener
renin
inhibitor
develop
six
decad
ago
limit
druglik
properti
suffer
poor
intestin
absorpt
high
liver
firstpass
metabol
low
oral
bioavail
develop
chemic
divers
molecul
peptid
nonpeptid
expand
horizon
achiev
direct
renin
inhibit
aliskiren
blockbust
drug
emerg
clinic
candid
got
approv
us
fda
develop
molecular
model
studi
aliskiren
indic
superior
averag
efficaci
minor
advers
effect
rel
ra
inhibitor
howev
therapeut
use
limit
poor
oral
bioavail
less
similar
firstgener
peptid
compound
review
present
develop
direct
renin
inhibitor
dri
peptid
nonpeptid
lead
birth
aliskiren
place
treatment
cardiovascular
diseas
limit
global
level
highest
mortal
cardiovascular
diseas
caus
accord
report
expect
million
individu
die
cardiovascular
ailment
repres
global
death
project
peopl
die
heart
diseas
stroke
hypertens
multifacet
cvd
signific
hazard
factor
heart
attack
heart
failur
chronic
kidney
diseas
renal
damag
stroke
likewis
predomin
patient
diabet
mellitu
left
untreat
advanc
endorgan
damag
heart
kidney
eventu
lead
death
diagnosi
manag
adult
hypertens
patient
new
guidelin
publish
american
colleg
cardiolog
new
rule
character
normal
blood
pressur
less
mm
hg
elev
blood
pressur
mm
hg
systol
less
mm
hg
diastol
would
reclassifi
peopl
previous
consid
prehypertens
hypertens
furthermor
guidelin
recommend
aggress
approach
combat
high
blood
pressur
treatment
regimen
often
involv
one
class
drug
novel
target
manag
blood
pressur
one
sever
class
drug
approv
chronic
treatment
hypertens
drug
interrupt
reninangiotensinaldosteron
axi
pathway
consid
signific
scientif
advanc
treatment
hypertens
cardiovascular
ailment
among
ra
inhibitor
dri
yet
gain
notch
treatment
cardiovascular
kidney
diseas
review
discuss
develop
renin
inhibitor
sever
decad
old
discoveri
peptid
nonpeptid
recent
develop
continu
unearth
dri
therapeut
potenti
aliskiren
approv
renin
inhibitor
sinc
cardiovascular
renal
adren
gland
control
ra
manag
blood
pressur
sodium
potassium
balanc
fluid
volum
studi
goldblatt
et
al
report
import
find
relat
renin
kidney
function
blood
pressur
sinc
extens
experiment
studi
undertaken
recogn
compon
ra
role
regul
blood
pressur
fluid
homeostasi
princip
compon
system
ang
ii
form
action
angiotensinconvert
enzym
ace
ang
fig
latter
form
cleavag
angiotensinogen
amino
acid
circul
globulin
renin
circul
level
renin
depend
sever
factor
interrupt
neg
feedback
decreas
ang
ii
receptor
site
acut
stimuli
juxtaglomerular
apparatu
kidney
treatment
receptor
blocker
ace
inhibitor
thu
format
renin
precursor
prorenin
consid
ratedetermin
step
synthesi
ang
angiotensinogen
overactiv
ra
result
excess
gener
ang
ii
activ
receptor
purport
caus
hypertens
heart
failur
ischem
diseas
atherosclerosi
cardiac
hypertrophi
renal
disord
thu
pharmacolog
agent
interrupt
perform
ra
counteract
event
ang
ii
reduc
synthesi
avoid
authorit
action
receptor
thu
abstract
ra
cascad
variou
level
differ
effect
compon
first
approach
block
action
enzym
renin
eg
aliskiren
synthesi
angiotensin
angiotensinogen
necessarili
prefer
choic
halt
gener
angiotensin
peptid
reninac
nonacechymas
pathway
second
approach
success
launch
introduct
captopril
ace
inhibitor
block
format
ang
ii
ang
ace
inhibitor
constitut
one
import
treatment
regimen
combat
high
blood
pressur
cardiac
insuffici
ace
inhibitor
use
manag
mild
moder
hypertens
myocardi
infarct
diabet
nephropathi
congest
heart
failur
third
approach
combat
hypertens
block
action
ang
ii
target
site
receptor
receptor
mediat
known
cardiovascular
effect
associ
ang
ii
ang
ii
receptor
blocker
eg
losartan
highli
effect
welltoler
antihypertens
medic
fourth
stage
block
product
aldosteron
import
compon
ra
known
caus
increas
sodium
retent
increas
volum
contribut
hypertens
thu
aldosteron
antagonist
eg
spironolacton
effect
reduc
blood
pressur
patient
afflict
essenti
hypertens
block
action
aldosteron
mineralocorticoid
receptor
beyond
fifth
approach
block
enzym
aldosteron
synthas
sixth
novel
approach
open
concurr
inhibit
receptor
neprilysin
eg
valsartansacubitril
combin
tigerstedt
bergman
reveal
pressor
impact
rabbit
renal
tissu
extract
name
substanc
renin
angiotensinogenas
current
known
renin
aspartyl
proteas
enzym
produc
juxtaglomerular
cell
kidney
renin
produc
prorenin
proteolyt
activ
remov
proseg
nonproteolyt
activ
respons
hypotens
hypernatremia
renin
discharg
blood
circul
prorenin
renin
bind
pro
renin
receptor
prorenin
renin
synthes
kidney
prorenin
also
produc
extraren
tissu
includ
collect
duct
adren
gland
retina
placenta
testi
submandibular
gland
ovari
numer
speci
plasma
prorenin
level
time
higher
plasma
renin
physiolog
condit
less
prorenin
turn
enzymat
dynam
chronic
patholog
stimuli
elev
activ
prorenin
level
increas
convers
activ
renin
sever
patholog
condit
ratio
prorenin
renin
may
reach
high
result
increas
ang
ii
level
level
renin
higher
patient
diabet
condit
adult
human
plasma
renin
normal
concentr
ngl
upstand
posit
renin
high
specif
angiotensinogen
renin
possess
two
homolog
flap
dynam
site
resid
deep
cleft
form
fig
catalyt
activ
dynam
site
two
aspart
acid
residu
one
flap
renin
molecul
key
element
dynam
site
discreet
sub
pocket
precis
among
aspart
proteas
specif
renin
dynam
site
accommod
seven
amino
acid
unit
substrat
angiotensinogen
cleav
peptid
bond
within
angiotensinogen
produc
ang
ratedetermin
step
appear
renin
inhibit
would
like
therapeut
target
succeed
far
activ
ra
mechan
concern
lack
confirm
highli
efficaci
dri
studi
ra
research
centuri
exclus
comprehend
job
typic
physiolog
function
yet
addit
expand
power
treatment
treat
overactiv
effici
research
endeavor
prompt
propos
noncanon
ra
pathway
challeng
hypothesi
ra
exert
deleteri
effect
renal
cardiovascular
system
ra
steadili
expand
discoveri
homologu
ace
carboxypeptidas
enzym
found
except
heart
kidney
blood
vessel
classic
system
renin
cleav
angiotensinogen
form
ang
ang
addit
substrat
form
ang
also
cleav
ang
ii
form
ang
also
form
action
ace
ang
ang
account
exert
invers
ang
ii
counterbal
undesir
effect
ang
ii
heart
kidney
blood
vessel
physiolog
function
ang
mediat
via
g
proteincoupl
receptor
ma
receptor
ma
r
thu
ra
exhibit
dual
action
major
one
well
character
convent
canon
pathway
aceang
r
axi
mediat
inflamm
via
vasoconstrict
prolifer
second
noncanon
pathway
ma
r
axi
wide
rang
influenc
oppos
modul
princip
canon
pathway
endotheli
protect
cardioprotect
natriuret
antiprolif
vasodilatori
properti
ra
show
dualiti
act
devil
canon
pathway
angel
noncanon
pathway
furthermor
might
interest
note
function
receptor
sinc
key
regul
cardiac
function
cardioprotect
effect
therapi
ra
inhibitor
includ
ace
inhibitor
arb
renin
inhibitor
cardiovascular
diseas
patient
done
great
care
renin
attract
target
ratedetermin
step
ang
ii
synthesi
renin
inhibitor
markedli
reduc
plasma
renin
activ
pra
consequ
limit
product
ang
angiotensinogen
reninac
nonacechymas
pathway
prevent
synthesi
angiotensin
peptid
past
three
decad
extens
work
done
renin
inhibitor
although
therapeut
signific
renin
inhibitor
recogn
sinc
investig
began
antibodi
peptid
first
peptid
renin
inhibitor
came
sever
year
investig
peptid
nonpeptid
transit
occur
research
design
renin
inhibitor
got
benefit
emerg
comput
molecular
model
techniqu
structurebas
drug
design
crystallograph
techniqu
firstli
prorenin
structur
report
later
renin
structur
report
facilit
medicin
chemist
move
fast
explor
renin
inhibitor
past
decad
extens
studi
done
discov
clinic
efficaci
renin
inhibitor
research
renin
inhibitor
began
peptid
synthesi
skeg
cowork
studi
serv
base
peptid
investig
renin
tetradecapeptid
substrat
sequenc
aspargvaltyrilehisprophehisleuleuvaltyrs
attempt
made
synthes
peptid
mimick
renin
segment
protein
hemoglobin
variou
speci
globin
chain
globin
fragment
plactoglobulin
b
fragment
show
inhibitori
action
renin
mid
renin
substrat
deriv
peptid
report
unsatur
peptid
deriv
activ
satur
peptid
polypeptid
ahmoavalpheoch
hisahmoavalpheoch
ahmoailehisoch
synthes
angiotensin
peptid
fragment
also
show
competit
inhibit
renin
enzym
later
structur
differ
peptid
tri
inclus
cyclohexylalanyl
analog
statin
acid
achpa
octapeptid
deriv
contribut
power
renin
inhibitor
potenc
retain
even
pentapeptid
seri
tetrapeptid
contain
statin
addit
variou
hydrophob
aromat
group
carboxi
terminu
show
competit
renin
inhibit
furthermor
activ
increas
seven
time
report
statin
time
statin
fluoro
keto
peptid
synthes
presenc
fluoro
group
increas
activ
time
bind
enzym
unsatur
fluoro
keto
peptid
show
activ
result
replac
peptid
tran
alken
oral
efficaci
achiev
synthes
oligopeptid
deriv
transform
glycopeptid
deriv
result
delay
hypotens
activ
human
renin
infus
rat
assay
structurebas
drug
design
sbdd
involv
xray
crystallographi
computerassist
molecular
model
develop
one
paramount
ideal
model
drug
discoveri
olefin
dipeptid
design
isoster
replac
amid
bond
show
renin
inhibitori
effect
human
amniot
renin
hog
kidney
renin
dipeptid
deriv
design
replac
amid
bond
ester
group
alter
activ
much
impli
amid
group
essenti
bind
hydrogen
bond
incorpor
sulphonamid
n
terminu
peptid
end
show
excel
renin
inhibitori
activ
merck
develop
member
macrocycl
renin
inhibitor
glutam
deriv
serin
deriv
macrocycl
develop
replac
amid
bond
ester
linkag
macrocycl
ring
modif
less
effect
potenc
glutam
seri
increas
potenc
observ
serin
seri
outcom
studi
potent
compound
quinuclidinylph
deriv
rhesu
monkey
reduc
blood
pressur
mm
hg
hinder
pra
show
less
oral
bioavail
rat
result
serineest
bond
cleavag
key
strategi
extens
structur
modif
peptid
deriv
integr
exclus
peptid
natur
improv
signific
bind
interact
renin
specif
idea
intend
accomplish
nomin
molecular
size
peptid
solid
bind
affin
wide
varieti
peptidomimet
synthes
sever
decad
restrict
druglik
properti
numer
drawback
importantli
low
intestin
absorpt
elev
liver
firstpass
metabol
result
poor
oral
bioavail
sever
gener
peptid
renin
inhibitor
develop
end
low
solubl
high
molecular
weight
poor
bioavail
thu
inevit
research
focu
nonpeptid
achiev
improv
oral
bioavail
past
decad
key
progress
medicin
chemistri
approach
contribut
brisk
intrigu
develop
promis
new
class
druggabl
moieti
show
renin
inhibit
chemic
divers
molecul
expand
horizon
achiev
target
molecul
resembl
transit
state
substrat
molecul
enzymecatalyz
chemic
reaction
develop
compound
includ
hexan
moieti
ctermin
function
assess
inhibit
renin
vivo
vitro
compound
exhibit
potenc
nanomolar
even
subnanomolar
concentr
rang
test
sodiumdeplet
rhesu
monkey
vivo
human
renin
vitro
one
potent
compound
ntermin
deriv
piperidyl
succin
acid
inhibit
human
renin
activ
ic
nm
sinc
high
put
screen
ht
emerg
discoveri
tool
mani
million
compound
produc
assess
activ
target
protein
low
success
rate
identif
potenti
hit
molecul
roch
came
piperidin
lead
moieti
systemat
optim
structur
class
result
piperidin
deriv
affin
renin
picomolar
rang
novarti
earlier
known
cibageigi
came
distinct
moieti
aminohydroxyethylen
dipeptid
isoster
emerg
piperidin
deriv
roch
novarti
led
new
insight
research
renin
inhibit
firstli
ketopiperazin
deriv
design
later
optim
ring
c
led
synthesi
aliskiren
time
research
move
peptid
nonpeptid
plant
activ
constitu
renin
inhibitori
effect
sodium
houttuynin
volatil
oil
extract
perenni
plant
houttunynia
cordata
thunb
seri
analog
sodium
houttuynin
demonstr
consider
renin
inhibitori
effect
rapid
intrigu
emerg
medicin
chemistri
methodolog
aim
design
druggabl
moieti
research
focus
synthet
divers
space
ligand
level
applic
novel
drug
design
tool
molecular
model
xray
crystallograph
studi
denovo
synthesi
fragmentbas
drug
design
structurebas
drug
design
tool
success
employ
identifi
ligand
bind
site
renin
dynam
site
hefti
flank
pocket
contribut
main
site
also
call
hot
spot
ligand
bind
site
highli
hydrophob
site
highli
hydrophob
complet
distinct
substrat
specif
pocket
extend
substratebind
topographi
appli
concept
structurebas
drug
design
roch
design
piperidin
molecul
deriv
compound
discov
ht
roch
fig
although
show
weak
activ
nevertheless
becam
backbon
discoveri
direct
renin
inhibitor
similarli
substitut
deriv
pfizer
show
weak
renin
inhibit
fig
modif
phenyl
group
replac
highli
electroneg
halogen
moieti
increas
activ
sevenfold
notic
identifi
new
scaffold
drug
discoveri
furthermor
optim
phenyl
moieti
bicycl
group
compound
exhibit
high
vitro
potenc
oral
bioavail
fig
although
mani
oral
activ
compound
enalkiren
remikerin
zenkiren
develop
found
clinic
ineffici
short
halflif
weak
antihypertens
activ
poor
bioavail
new
seri
nonen
deriv
develop
piperidin
templat
denovo
drug
design
optim
posit
diazabicyclonen
templat
led
discoveri
enantiom
compound
show
renin
inhibit
improv
pharmacokinet
properti
function
group
substitut
posit
found
crucial
bind
affin
compound
renin
structurebas
topolog
design
approach
deriv
exhibit
excel
oral
bioavail
improv
potenc
maibaum
et
al
modifi
posit
deriv
howev
posit
modif
hydroxyl
ethylen
transitionst
isoster
substanti
improv
potenc
durat
action
hard
work
led
innov
aliskiren
extrem
select
potent
renin
inhibit
sodiumdeplet
marmoset
oral
administr
aliskiren
dosedepend
reduc
mean
arteri
blood
pressur
sustain
durat
action
final
two
decad
research
success
discoveri
aliskiren
bind
renin
enzym
similar
peptid
chemic
describ
fig
n
phenyl
octanamid
aliskiren
discoveri
approv
treatment
hypertens
mani
research
work
renin
inhibit
succeed
synthes
sever
molecul
show
renin
inhibitori
activ
investig
carboxamid
deriv
continu
object
achiev
good
oral
bioavail
lack
aliskiren
mori
et
al
xray
crystallograph
studi
design
potent
renin
inhibitor
oral
bioavail
doubl
transgen
rat
model
hypertens
among
piperazin
deriv
nakamura
et
al
show
mark
renin
inhibitori
activ
inhibit
human
renin
nm
concentr
much
lower
aliskiren
nterminu
substitut
although
low
cardiac
toxic
suppress
pra
cynomolgu
monkey
effect
aliskiren
prove
clinic
ineffici
use
crystallograph
techniqu
comput
molecular
model
scientist
sever
pharmaceut
compani
synthes
sever
potent
select
renin
inhibitor
number
compound
gain
worldwid
attent
describ
vitaegsk
alkyl
amin
base
dri
design
structurebas
drug
design
de
novo
drug
design
fig
compound
show
nearli
inhibit
pra
daiichi
sankyo
research
focus
mainli
aliskirenbas
deriv
achiev
improv
oral
bioavail
contrast
roch
piperidin
daiichi
sankyo
design
fig
compound
scaffold
demonstr
good
bind
renin
similar
novarti
design
compound
fig
high
throughput
screen
pyrrolidin
compound
fig
comput
techniqu
report
new
class
renin
inhibitor
actelionmerck
actelion
design
nonen
deriv
use
roch
basic
scaffold
structurebas
drug
design
collabor
merck
optim
actelion
lead
develop
compound
fig
well
toler
phase
ii
clinic
trial
fail
lower
blood
pressur
even
week
treatment
anoth
similar
molecul
compound
fig
develop
actelionmerck
show
drug
interact
atorvastatin
simvastatin
fig
merckfrost
optim
piperidin
deriv
molecular
model
studi
lead
identif
methylen
amin
transit
state
analog
fig
dainipponsumitomo
design
compound
deriv
one
molecul
exhibit
oral
efficaci
dtgr
model
furthermor
demonstr
advers
antiinflammatori
effect
fig
mitsubishitanab
design
two
deriv
fig
substitut
posit
takeda
design
piperidin
base
transit
state
analog
heterocycl
carboxamid
group
optim
physicochem
properti
piperidin
analog
led
innov
benzimidazol
deriv
n
n
hydrochlorid
potent
oral
activ
inhibit
enzym
concentr
fig
addit
show
cardioprotect
activ
plexxikon
design
tetrahydroquinolin
deriv
ic
renin
inhibit
fig
cadila
healthcar
design
deriv
amid
spacer
improv
lipophil
achiev
good
oral
efficaci
fig
sanofiaventi
design
chiral
deriv
compound
fig
high
throughput
screen
bind
conform
renin
similar
aliskiren
optim
molecul
structurebas
drug
design
yield
azaindol
deriv
increas
potenc
compound
fig
describ
mani
compani
invest
time
money
research
produc
hundr
compound
demonstr
good
renin
inhibitor
activ
howev
fail
meet
clinic
develop
program
far
seem
success
limit
one
compound
aliskiren
foremost
prototyp
dri
class
approv
us
food
drug
administr
march
manag
hypertens
next
section
describ
pharmacolog
pharmacokinet
therapeut
potenti
aliskiren
treat
cardiovascular
renal
disord
aliskiren
highli
potent
specif
bind
human
renin
enzym
aliskiren
dual
action
reninangiotensin
system
distinct
pra
reduct
power
differ
antihypertens
drug
acei
arb
clinic
aliskiren
well
toler
sympathet
neurohormon
effect
heart
failur
aliskiren
effect
left
ventricular
wall
thick
volum
left
ventricular
eject
fraction
conceiv
short
span
activ
compar
small
sampl
size
larger
longerterm
studi
expect
demonstr
invalid
theori
aliskiren
monotherapi
well
combin
therapi
antihypertens
show
mark
effect
well
toler
drug
choic
long
term
treatment
blood
pressur
aliskiren
neuroprotect
action
effect
diabet
patient
unfortun
research
apprehens
may
provid
practic
obstacl
aliskiren
research
renin
inhibitor
prevent
vascular
injuri
caus
high
blood
pressur
therebi
tender
consider
secur
cardioprotect
renoprotect
follow
oral
administr
aliskiren
quickli
poorli
absorb
reach
peak
plasma
concentr
within
hr
administr
halflif
hr
steadyst
plasma
concentr
aliskiren
reach
day
oral
daili
dose
highfat
meal
decreas
aliskiren
absorpt
aliskiren
favor
physicochem
properti
high
water
solubl
mgml
ph
high
hydrophil
log
p
octwat
ph
essenti
properti
good
oral
bioavail
less
affin
relat
aspart
peptidas
howev
report
bioavail
approxim
aliskiren
moder
bind
plasma
protein
mean
proteinbound
level
clinic
relev
pharmacokinet
pharmacodynam
effect
influenc
neither
bodi
weight
sex
meal
impact
pharmacokinet
drug
candid
oral
administr
aliskiren
mg
food
diminish
mean
cmax
auc
valu
lower
respect
fast
state
highfat
meal
decreas
auc
cmax
valu
respect
fast
state
thu
patient
advis
take
aliskiren
similar
way
everi
day
adher
meal
time
aliskiren
lower
potenti
consider
drug
interact
remark
aliskiren
metabol
human
substrat
enzym
suppress
enzym
thu
make
appropri
drug
combin
antihypertens
agent
aliskiren
elimin
unalt
hepatobiliari
rout
absorpt
less
excret
urin
hepat
elimin
aliskiren
make
safe
patient
renal
impair
necess
dose
adjust
patient
hepat
renal
impair
elderli
patient
hypertens
fundament
hazard
factor
cardiovascular
diseas
stroke
chronic
kidney
diseas
diabet
mellitu
patient
suffer
high
blood
pressur
chronic
hypertens
lead
progress
endorgan
damag
kidney
heart
lead
high
morbid
preclus
blood
pressur
decis
watanab
herit
hyperlipidem
rabbit
aliskiren
mgkg
shown
recov
impair
nitric
oxid
bioavail
vascular
endothelium
protect
atherosclerot
chang
coronari
arteri
ligat
mous
model
myocardi
infarct
aliskiren
notic
improv
structur
variat
cardiac
activ
anoth
studi
aliskiren
show
promin
effect
prevent
cardiac
fibrosi
oxid
stress
diabet
rat
effici
ace
inhibitor
aliskiren
alon
combin
losartan
well
toler
signifi
aliskiren
effici
well
toler
treatment
choic
patient
left
ventricular
hypertrophi
doubl
transgen
rat
aliskiren
effect
candesartan
cerebr
ischem
stroke
aliskiren
notabl
enhanc
brain
water
content
infarct
volum
nissl
bodi
neurolog
score
patient
cerebr
ischemia
neuroprotect
outcom
aliskiren
independ
blood
pressur
lower
effect
aliskiren
alon
combin
therapi
valsartan
ramipril
hydrochlorothiazid
provid
addit
lower
effect
diabet
patient
highrisk
hypertens
may
note
aliskiren
longer
use
combin
ra
inhibitor
gener
inhibit
ra
pathway
recommend
firstlin
therapi
treatment
renal
complic
renoprotect
effect
aliskiren
also
shown
doubl
transgen
rat
dtgr
express
gene
angiotensinogen
human
renin
renal
vasodil
normotens
subject
lowsodium
diet
significantli
induc
aliskiren
respons
exceed
report
ace
inhibitor
angiotensin
receptor
blocker
arb
durat
long
accompani
consider
natriuresi
renal
insuffici
patient
aliskiren
provid
inclus
signific
blockad
ra
improv
renal
effici
aliskiren
found
antiinflammatori
effect
kidney
aliskiren
also
provid
renal
protect
decreas
albuminuria
patient
diabet
suggest
aliskiren
renoprotect
compar
antihypertens
renoprotect
impact
aliskiren
independ
although
aliskiren
possess
cardioprotect
renoprotect
effect
suffer
poor
bioavail
seriou
advers
effect
hyperkalemia
renal
dysfunct
guid
increas
mortal
morbid
aliskiren
studi
postmi
patient
reduc
remodel
aspir
studi
investig
favor
combin
therapi
aliskiren
ra
inhibitor
diabet
patient
aliskiren
trial
minim
outcom
patient
heart
failur
atmospher
trial
investig
reveal
dual
therapi
enalapril
patient
high
rate
hypotens
renal
dysfunct
may
benefici
aliskiren
dosag
mgday
caus
gastrointestin
symptom
dyspepsia
abdomin
pain
gastrointestin
reflux
classic
mild
often
lead
stoppag
treatment
aliskiren
trial
type
diabet
use
cardioren
endpoint
altitud
trail
investig
reveal
addit
aliskiren
standard
therapi
ra
blockad
patient
type
diabet
impact
cardiovascular
renal
event
may
even
detriment
aliskiren
trial
acut
heart
failur
outcom
astronaut
trial
reveal
addit
aliskiren
standard
therapi
lessen
rate
heart
failur
cardiovascular
death
aliskiren
quantit
atherosclerosi
regress
intravascular
ultrasound
studi
aquariu
investig
conclud
aliskiren
treatment
caus
consider
improv
arrest
progress
coronari
atherosclerosi
signific
effect
risk
chief
cardiovascular
function
aliskiren
combin
therapi
losartan
diuret
may
caus
addit
threat
hyperkalemia
result
renal
dysfunct
essenti
hypertens
renin
catalyz
initi
phase
ra
cascad
regul
homeostasi
bodi
fluid
volum
blood
pressur
renin
inhibitor
attract
drug
candid
manag
hypertens
cardiovascularrel
disord
direct
renin
inhibitor
aliskiren
emerg
clinic
effici
molecul
till
today
aliskiren
ketopiperazin
deriv
good
bind
high
specif
renin
enzym
sever
hundr
research
tri
follow
bind
pattern
aliskiren
renin
enzym
synthes
mani
renin
inhibitor
vast
number
medicin
chemist
design
new
chemic
molecul
use
structurebas
drug
design
de
novo
drug
design
molecular
model
studi
howev
none
new
chemic
entiti
found
clinic
effici
rel
aliskiren
suffer
poor
bioavail
short
halflif
weak
antihypertens
efficaci
high
lipophil
high
molecular
weight
larg
number
rotat
bond
develop
newer
renin
inhibitor
improv
clinic
efficaci
safeti
rel
aliskiren
still
elus
discoveri
new
druggabl
moieti
demand
new
antihypertens
expect
exhibit
appar
divers
clinic
profil
beyond
reduct
blood
pressur
